Clinical trial
Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00036036 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00036036 |
|---|---|
| Title | Study of CP-461 in Patients With Advanced Renal Cell Cancer |
| Official title | Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | CP-461 |
| Enrollment | 14 |
| Start date | Jul 1, 2001 |
| Completion | Jul 1, 2003 |
| First posted | May 8, 2002 |
| Last update posted | Oct 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: